

Giuseppe Danilo Norata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5306139/publications.pdf>

Version: 2024-02-01

179
papers

10,154
citations

26630

56
h-index

39675

94
g-index

182
all docs

182
docs citations

182
times ranked

16820
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of seven loci affecting mean telomere length and their association with disease. <i>Nature Genetics</i> , 2013, 45, 422-427.	21.4	808
2	LOX-1, OxLDL, and Atherosclerosis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-12.	3.0	548
3	High-Density Lipoprotein Subfractions - What the Clinicians Need to Know. <i>Cardiology</i> , 2013, 124, 116-125.	1.4	509
4	Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis. <i>Circulation</i> , 2009, 120, 699-708.	1.6	252
5	HDL in innate and adaptive immunity. <i>Cardiovascular Research</i> , 2014, 103, 372-383.	3.8	236
6	Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. <i>Immunity</i> , 2017, 47, 875-889.e10.	14.3	181
7	Plasma resistin levels correlate with determinants of the metabolic syndrome. <i>European Journal of Endocrinology</i> , 2007, 156, 279-284.	3.7	176
8	Leptin:Adiponectin Ratio Is an Independent Predictor of Intima Media Thickness of the Common Carotid Artery. <i>Stroke</i> , 2007, 38, 2844-2846.	2.0	164
9	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. <i>Cardiovascular Research</i> , 2021, 117, 29-42.	3.8	164
10	The Cellular and Molecular Basis of Translational Immunometabolism. <i>Immunity</i> , 2015, 43, 421-434.	14.3	161
11	Emerging role of high density lipoproteins as a player in the immune system. <i>Atherosclerosis</i> , 2012, 220, 11-21.	0.8	158
12	PI3K-C21 ³ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. <i>Nature Communications</i> , 2015, 6, 7400.	12.8	155
13	HDL in Infectious Diseases and Sepsis. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 483-508.	1.8	145
14	Apolipoprotein C-III: From Pathophysiology to Pharmacology. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 675-687.	8.7	144
15	Dihydrotestosterone Decreases Tumor Necrosis Factor- α and Lipopolysaccharide-Induced Inflammatory Response in Human Endothelial Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 546-554.	3.6	139
16	Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 925-931.	2.4	137
17	The Long Pentraxin PTX3: A Modulator of the Immunoinflammatory Response in Atherosclerosis and Cardiovascular Diseases. <i>Trends in Cardiovascular Medicine</i> , 2010, 20, 35-40.	4.9	136
18	Markers of Inflammation Associated with Plaque Progression and Instability in Patients with Carotid Atherosclerosis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-15.	3.0	135

#	ARTICLE	IF	CITATIONS
19	Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. <i>Atherosclerosis</i> , 2007, 191, 265-271.	0.8	131
20	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. <i>Journal of Experimental Medicine</i> , 2015, 212, 905-925.	8.5	128
21	Circulating CD4 ⁺ CD25 ^{hi} CD127 ^{lo} Regulatory T-Cell Levels Do Not Reflect the Extent or Severity of Carotid and Coronary Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1832-1841.	2.4	125
22	Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4 + T Cell Differentiation via PI3K p110 β -Akt-Mediated Signals. <i>Cell Metabolism</i> , 2017, 25, 593-609.	16.2	124
23	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. <i>European Heart Journal</i> , 2019, 40, 357-368.	2.2	124
24	Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: Molecular mechanisms and gene expression studies. <i>Atherosclerosis</i> , 2007, 193, 321-327.	0.8	122
25	Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. <i>Journal of the American Heart Association</i> , 2012, 1, 27-41.	3.7	114
26	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. <i>Cardiovascular Research</i> , 2016, 112, 429-442.	3.8	105
27	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. <i>British Journal of Pharmacology</i> , 2017, 174, 3973-3985.	5.4	105
28	Targeting PCSK9 for Hypercholesterolemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 273-293.	9.4	96
29	Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure to function relation to therapeutic inhibition. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 835-843.	2.6	95
30	Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. <i>Nature Communications</i> , 2018, 9, 3083.	12.8	95
31	Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 129-134.	2.6	94
32	Postprandial lipemia as a cardiometabolic risk factor. <i>Current Medical Research and Opinion</i> , 2014, 30, 1489-1503.	1.9	94
33	HDL ₃ Induces Cyclooxygenase-2 Expression and Prostacyclin Release in Human Endothelial Cells Via a p38 MAPK/CRE-Dependent Pathway: Effects on COX-2/PGI-Synthase Coupling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 871-877.	2.4	92
34	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. <i>Cell Metabolism</i> , 2014, 20, 787-798.	16.2	92
35	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. <i>European Heart Journal</i> , 2013, 34, 1783-1789.	2.2	90
36	Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	3.0	89

#	ARTICLE	IF	CITATIONS
37	MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr ^{-/-} mice. <i>Thrombosis and Haemostasis</i> , 2014, 112, 796-802.	3.4	87
38	A past and present overview of macrophage metabolism and functional outcomes. <i>Clinical Science</i> , 2017, 131, 1329-1342.	4.3	87
39	High-Density Lipoproteins Induce Transforming Growth Factor- β 2 Expression in Endothelial Cells. <i>Circulation</i> , 2005, 111, 2805-2811.	1.6	84
40	The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis. <i>Mediators of Inflammation</i> , 2019, 2019, 1-11.	3.0	79
41	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. <i>Atherosclerosis</i> , 2016, 246, 208-213.	0.8	78
42	Cholesterol metabolism, pancreatic β -cell function and diabetes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2149-2156.	3.8	76
43	Modified HDL: Biological and physiopathological consequences. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 371-386.	2.6	75
44	Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. <i>Journal of Internal Medicine</i> , 2005, 258, 21-27.	6.0	74
45	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. <i>Atherosclerosis</i> , 2010, 208, 177-182.	0.8	74
46	Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 194-205.	1.8	74
47	Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. <i>Atherosclerosis</i> , 2009, 206, 556-562.	0.8	69
48	Long Pentraxin 3/Tumor Necrosis Factor-Stimulated Gene-6 Interaction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 696-703.	2.4	69
49	High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. <i>Journal of Internal Medicine</i> , 2013, 274, 252-262.	6.0	68
50	Carotid Intima-Media Thickness Progression and Risk of Vascular Events in People With Diabetes: Results From the PROG-IMT Collaboration. <i>Diabetes Care</i> , 2015, 38, 1921-1929.	8.6	67
51	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2018, 20, 12.	4.8	67
52	Biological Consequences of Dysfunctional HDL. <i>Current Medicinal Chemistry</i> , 2019, 26, 1644-1664.	2.4	65
53	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019, 115, 510-518.	3.8	63
54	Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. <i>Vascular Health and Risk Management</i> , 2005, 1, 119-129.	2.3	63

#	ARTICLE	IF	CITATIONS
55	Effect of the ?420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. <i>Journal of Internal Medicine</i> , 2007, 262, 104-112.	6.0	60
56	Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. <i>Cardiovascular Research</i> , 2003, 59, 169-180.	3.8	59
57	Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: Molecular mechanisms and gene expression studies. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 40, 484-494.	1.9	55
58	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1870-1877.	1.8	55
59	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. <i>British Journal of Haematology</i> , 2004, 127, 97-104.	2.5	53
60	Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 379-395.	2.6	52
61	Immunometabolic function of cholesterol in cardiovascular disease and beyond. <i>Cardiovascular Research</i> , 2019, 115, 1393-1407.	3.8	52
62	Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk – Results from the PROG-IMT collaboration. <i>PLoS ONE</i> , 2018, 13, e0191172.	2.5	51
63	Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. <i>European Heart Journal</i> , 2020, 41, 2487-2497.	2.2	50
64	PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3078-3090.	2.2	50
65	Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population. <i>Journal of Internal Medicine</i> , 2015, 277, 478-487.	6.0	49
66	Effects of Fractalkine Receptor Variants on Common Carotid Artery Intima-Media Thickness. <i>Stroke</i> , 2006, 37, 1558-1561.	2.0	48
67	Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. <i>Atherosclerosis</i> , 2010, 210, 78-87.	0.8	48
68	Statins and skeletal muscles toxicity: From clinical trials to everyday practice. <i>Pharmacological Research</i> , 2014, 88, 107-113.	7.1	48
69	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 106, 55-67.	1.9	45
70	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. <i>Frontiers in Immunology</i> , 2019, 10, 571.	4.8	43
71	Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 141-153.	2.6	42
72	HDLs, immunity, and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2011, 22, 410-416.	2.7	41

#	ARTICLE	IF	CITATIONS
73	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0162473.	2.5	41
74	New Pharmacological Approaches to Target PCSK9. <i>Current Atherosclerosis Reports</i> , 2020, 22, 24.	4.8	41
75	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 751-759.	2.6	39
76	Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project. <i>American Heart Journal</i> , 2010, 159, 730-736.e2.	2.7	37
77	The androgen derivative 5 α -androstane-3 β ,17 β -diol inhibits tumor necrosis factor α and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. <i>Atherosclerosis</i> , 2010, 212, 100-106.	0.8	37
78	Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 455-482.	1.8	37
79	MicroRNAs and lipoproteins: A connection beyond atherosclerosis?. <i>Atherosclerosis</i> , 2013, 227, 209-215.	0.8	36
80	Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. <i>Cardiovascular Research</i> , 2019, 115, 1861-1872.	3.8	36
81	P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. <i>Cancer Research</i> , 2020, 80, 3906-3919.	0.9	36
82	Caloric Restriction Promotes Immunometabolic Reprogramming Leading to Protection from Tuberculosis. <i>Cell Metabolism</i> , 2021, 33, 300-318.e12.	16.2	35
83	Lysosomal Acid Lipase: From Cellular Lipid Handler to Immunometabolic Target. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 104-115.	8.7	34
84	Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin?. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1165-1173.	1.8	33
85	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. <i>Cardiovascular Research</i> , 2021, 117, 1033-1045.	3.8	33
86	High-density lipoprotein subfraction 3 decreases ADAMTS-1 expression induced by lipopolysaccharide and tumor necrosis factor- α in human endothelial cells. <i>Matrix Biology</i> , 2004, 22, 557-560.	3.6	32
87	Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1182-1190.	3.8	32
88	Circulating CD14 ⁺ and CD14 ^{high} CD16 ⁺ classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. <i>Atherosclerosis</i> , 2016, 255, 171-178.	0.8	32
89	Novel concepts in HDL pharmacology. <i>Cardiovascular Research</i> , 2014, 103, 423-428.	3.8	31
90	Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 518-523.	2.6	31

#	ARTICLE	IF	CITATIONS
91	Disease trends over time and CD4 + CCR5 + T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 53-63.	2.6	31
92	Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. <i>Cardiovascular Research</i> , 2021, 117, 2069-2082.	3.8	31
93	PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges. <i>Vascular Pharmacology</i> , 2014, 62, 103-111.	2.1	30
94	Matrix metalloproteinase-26 (Matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. <i>Gynecologic Oncology</i> , 2004, 94, 661-670.	1.4	29
95	Plasma adiponectin levels in chronic kidney disease patients: Relation with molecular inflammatory profile and metabolic status. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 56-63.	2.6	29
96	Microrna 143-145 Deficiency Impairs Vascular Function. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 467-474.	2.1	29
97	Gene silencing approaches for the management of dyslipidaemia. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 198-205.	8.7	29
98	The Interconnection Between Immuno-Metabolism, Diabetes, and CKD. <i>Current Diabetes Reports</i> , 2019, 19, 21.	4.2	28
99	Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality. <i>Current Pharmaceutical Design</i> , 2013, 19, 3841-3857.	1.9	27
100	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. <i>Current Atherosclerosis Reports</i> , 2020, 22, 18.	4.8	26
101	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 341-346.	1.9	23
102	Zc3h10 is a novel mitochondrial regulator. <i>EMBO Reports</i> , 2018, 19, .	4.5	23
103	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. <i>Cells</i> , 2021, 10, 1061.	4.1	23
104	Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis. <i>PLoS ONE</i> , 2013, 8, e53808.	2.5	23
105	Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. <i>Current Atherosclerosis Reports</i> , 2021, 23, 79.	4.8	23
106	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. <i>Pharmacological Research</i> , 2018, 130, 1-11.	7.1	22
107	Combination therapy in cholesterol reduction: focus on ezetimibe and statins. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 267-278.	2.3	21
108	HDL and adaptive immunity: A tale of lipid rafts. <i>Atherosclerosis</i> , 2012, 225, 34-35.	0.8	21

#	ARTICLE	IF	CITATIONS
109	Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population. <i>PLoS ONE</i> , 2012, 7, e31086.	2.5	21
110	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. <i>Thrombosis and Haemostasis</i> , 2015, 114, 186-197.	3.4	21
111	The CD1d-Natural Killer T Cell Axis in Atherosclerosis. <i>Journal of Innate Immunity</i> , 2014, 6, 3-12.	3.8	20
112	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. <i>Immunobiology</i> , 2015, 220, 1025-1029.	1.9	20
113	High density lipoproteins and atherosclerosis: emerging aspects. <i>Journal of Geriatric Cardiology</i> , 2013, 9, 401-407.	0.2	20
114	Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2289.	2.4	19
115	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. <i>Current Opinion in Lipidology</i> , 2019, 30, 462-469.	2.7	18
116	Homozygous familial hypobetalipoproteinemia: Two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. <i>Atherosclerosis</i> , 2015, 239, 209-217.	0.8	17
117	Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates <i>BCAR1</i> and Suggests a Causal Variant. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 696-706.	5.1	17
118	In silico drug repurposing in COVID-19: A network-based analysis. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111954.	5.6	17
119	Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis. <i>Nutrients</i> , 2021, 13, 304.	4.1	16
120	Effect of Lipids and Lipoproteins on Hematopoietic Cell Metabolism and Commitment in Atherosclerosis. <i>Immunometabolism</i> , 2021, 3, e210014.	1.6	16
121	Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues. <i>FASEB Journal</i> , 2022, 36, e22107.	0.5	16
122	Prevalence of classical CD14 ⁺⁺ /CD16 ⁺ but not of intermediate CD14 ⁺⁺ /CD16 ⁺ monocytes in hypoalphalipoproteinemia. <i>International Journal of Cardiology</i> , 2013, 168, 2886-2889.	1.7	15
123	Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models. <i>PLoS ONE</i> , 2020, 15, e0240669.	2.5	15
124	Lipid lowering activity of drugs affecting cholesterol absorption. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 42-51.	2.6	14
125	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 343-351.	2.3	14
126	Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. <i>Molecular Aspects of Medicine</i> , 2021, 77, 100918.	6.4	13

#	ARTICLE	IF	CITATIONS
127	Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2003, 12, 73-8.	4.0	13
128	HDL: To Treat or Not To Treat?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 429.	4.8	12
129	Monocarboxylate transporter 1 deficiency impacts CD8+ T lymphocytes proliferation and recruitment to adipose tissue during obesity. <i>IScience</i> , 2022, 25, 104435.	4.1	12
130	LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e58.	5.1	11
131	-374 T/A RAGE Polymorphism Is Associated with Chronic Kidney Disease Progression in Subjects Affected by Nephrocardiovascular Disease. <i>PLoS ONE</i> , 2013, 8, e60089.	2.5	11
132	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2006, 18, 209-13.	4.0	11
133	IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population. <i>PLoS ONE</i> , 2015, 10, e0122414.	2.5	10
134	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 234-243.	1.8	10
135	DDASSQ: An open-source, multiple peptide sequencing strategy for label free quantification based on an OpenMS pipeline in the KNIME analytics platform. <i>Proteomics</i> , 2021, 21, e2000319.	2.2	10
136	Defective lipid signalling caused by mutations in <i>PIK3C2B</i> underlies focal epilepsy. <i>Brain</i> , 2022, 145, 2313-2331.	7.6	10
137	Triglyceride-Rich Lipoproteins From Normotriglyceridemic Subjects and Hyperlipidemic Patients Differently Affect Endothelial Cell Activation and Gene Expression Patterns. <i>Circulation Research</i> , 2007, 100, e81.	4.5	9
138	Leonurine: A new comer in the natural compounds affecting atherosclerosis. <i>Atherosclerosis</i> , 2012, 224, 37-38.	0.8	9
139	Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 927-935.	3.8	9
140	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. <i>Annals of Medicine</i> , 2022, 54, 1036-1046.	3.8	9
141	Beyond LDL-C levels, does remnant cholesterol estimation matter?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1088-1090.	1.8	8
142	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	8
143	Antigen-Dependent and Antigen-Independent Pathways Modulate CD4 ⁺ CD28 ^{null} T-Cells During Atherosclerosis. <i>Circulation Research</i> , 2012, 111, e48-9; author reply e50-1.	4.5	7
144	The Thyroid Receptor Modulator KB3495 Reduces Atherosclerosis Independently of Total Cholesterol in the Circulation in ApoE Deficient Mice. <i>PLoS ONE</i> , 2013, 8, e78534.	2.5	7

#	ARTICLE	IF	CITATIONS
145	Trained immunity and cardiovascular disease: is it time for translation to humans?. <i>Cardiovascular Research</i> , 2018, 114, e41-e42.	3.8	7
146	Metabolomics, Lipidomics, and Immunometabolism. <i>Methods in Molecular Biology</i> , 2021, 2285, 319-328.	0.9	7
147	A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 701275.	4.8	7
148	Recent insights into low-density lipoprotein metabolism and therapy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 120-126.	2.5	7
149	Loss of voltage-gated hydrogen channel 1 expression reveals heterogeneous metabolic adaptation to intracellular acidification by T cells. <i>JCI Insight</i> , 2022, 7, .	5.0	7
150	Insights from ORION studies: focus on inclisiran safety. <i>Cardiovascular Research</i> , 2021, 117, 24-26.	3.8	6
151	Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Increased Coronary Atherosclerosis in the Absence of Hyperlipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 839-856.	2.4	6
152	ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 543-548.	2.1	5
153	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 721-729.	1.8	5
154	Fuel for thought: immunometabolism is a paradigm shift in understanding immunity in cardiovascular disease. <i>Cardiovascular Research</i> , 2019, 115, 1383-1384.	3.8	4
155	HDL and endothelial function: from molecular mechanisms to clinical observations. <i>Future Lipidology</i> , 2006, 1, 343-355.	0.5	3
156	Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?. <i>Atherosclerosis</i> , 2014, 234, 381-382.	0.8	3
157	Molecular Mechanisms Responsible for the Anti-Inflammatory and Protective Effect of High-Density Lipoprotein on the Endothelium. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 21-31.	2.2	2
158	Established and Emerging Approaches for the Management of Dyslipidaemia. <i>Scientifica</i> , 2012, 2012, 1-14.	1.7	2
159	Pharmacogenetics in Cardiovascular Disorders: An Update on the Principal Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 79-85.	2.2	2
160	Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States. <i>Contemporary Diabetes</i> , 2014, , 125-139.	0.0	2
161	Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events. <i>International Journal of Cardiology</i> , 2016, 223, 43-45.	1.7	2
162	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017, 28, 458-464.	2.7	2

#	ARTICLE	IF	CITATIONS
163	Inhibition of synthesis and absorption of cholesterol: A new option in managing hypercholesterolemia. International Congress Series, 2007, 1303, 121-128.	0.2	1
164	Therapy and clinical trials. Current Opinion in Lipidology, 2011, 22, 324-325.	2.7	1
165	Targeting Cholesterol in Non-Ischemic Heart Failure: A Role for LDLR Gene Therapy?. Molecular Therapy, 2017, 25, 2435-2437.	8.2	1
166	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
167	Dyslipidaemia and regulatory T-cell migration: an immunometabolic connection?. Cardiovascular Research, 2021, 117, 1235-1237.	3.8	1
168	Association between the Adherence to AHA Step 1 Nutrition Criteria and the Cardiometabolic Outcome in the General Population a Two Year Follow-Up Study. Food and Nutrition Sciences (Print), 2012, 03, 274-280.	0.4	1
169	Triglyceride-rich lipoproteins and endothelial dysfunction: molecular mechanisms and gene expression studies. Future Lipidology, 2007, 2, 119-122.	0.5	0
170	Response to Letter by Kotani et al. Stroke, 2008, 39, .	2.0	0
171	Lecithin:cholesterol acyltransferase and vascular disease. Clinical Lipidology, 2010, 5, 13-15.	0.4	0
172	Novel biotinylated bile acid amphiphiles: Micellar aggregates formation and interaction with hepatocytes. Organic and Biomolecular Chemistry, 2011, 9, 2899.	2.8	0
173	The Missing Link Between High-Density Lipoprotein Cholesterol and Inflammatory Response in Cardiovascular Disease. Journal of the American College of Cardiology, 2014, 63, 2747-2748.	2.8	0
174	New therapeutic principles for Familial Hypercholesterolemia. Clinical Biochemistry, 2014, 47, 756.	1.9	0
175	Hormonal control of trained immunity: aldosterone at the crossroad between activation of innate immunity and cardiovascular diseases. Cardiovascular Research, 2019, 116, 256-257.	3.8	0
176	Novel acquisitions in cell immunometabolism. Molecular Aspects of Medicine, 2021, 77, 100945.	6.4	0
177	Cholesterol Absorption Inhibitors. , 2009, , 288-297.		0
178	Pentraxins and Atherosclerosis. , 2012, , 219-237.		0
179	Interleukin 1 receptor 8 deficiency does not impact atherosclerosis. Thrombosis and Haemostasis, 2022, 0, .	3.4	0